Asunto(s)
Herpesvirus Humano 6 , Inmunoterapia Adoptiva , Receptores Quiméricos de Antígenos , Infecciones por Roseolovirus , Humanos , Herpesvirus Humano 6/inmunología , Inmunoterapia Adoptiva/efectos adversos , Inmunoterapia Adoptiva/métodos , Receptores Quiméricos de Antígenos/inmunología , Infecciones por Roseolovirus/inmunología , Infecciones por Roseolovirus/complicaciones , Linfocitos T/inmunología , Masculino , FemeninoRESUMEN
Introduction: Human Herpesvirus 6B (HHV-6B) impedes host immune responses by downregulating class I MHC molecules (MHC-I), hindering antigen presentation to CD8+ T cells. Downregulation of MHC-I disengages inhibitory receptors on natural killer (NK) cells, resulting in activation and killing of the target cell if NK cell activating receptors such as NKG2D have engaged stress ligands upregulated on the target cells. Previous work has shown that HHV-6B downregulates three MHC-like stress ligands MICB, ULBP1, and ULBP3, which are recognized by NKG2D. The U20 glycoprotein of the related virus HHV-6A has been implicated in the downregulation of ULBP1, but the precise mechanism remains undetermined. Methods: We set out to investigate the role of HHV-6B U20 in modulating NK cell activity. We used HHV-6B U20 expressed as a recombinant protein or transduced into target cells, as well as HHV-6B infection, to investigate binding interactions with NK cell ligands and receptors and to assess effects on NK cell activation. Small-angle X-ray scattering was used to align molecular models derived from machine-learning approaches. Results: We demonstrate that U20 binds directly to ULBP1 with sub-micromolar affinity. Transduction of U20 decreases NKG2D binding to ULBP1 at the cell surface but does not decrease ULBP1 protein levels, either at the cell surface or in toto. HHV-6B infection and soluble U20 have the same effect. Transduction of U20 blocks NK cell activation in response to cell-surface ULBP1. Structural modeling of the U20 - ULBP1 complex indicates some similarities to the m152-RAE1γ complex.
Asunto(s)
Proteínas Ligadas a GPI , Herpesvirus Humano 6 , Células Asesinas Naturales , Activación de Linfocitos , Subfamilia K de Receptores Similares a Lectina de Células NK , Humanos , Células Asesinas Naturales/inmunología , Células Asesinas Naturales/metabolismo , Herpesvirus Humano 6/inmunología , Proteínas Ligadas a GPI/metabolismo , Proteínas Ligadas a GPI/inmunología , Subfamilia K de Receptores Similares a Lectina de Células NK/metabolismo , Subfamilia K de Receptores Similares a Lectina de Células NK/inmunología , Activación de Linfocitos/inmunología , Unión Proteica , Proteínas Virales/inmunología , Proteínas Virales/metabolismo , Glicoproteínas/inmunología , Glicoproteínas/metabolismo , Péptidos y Proteínas de Señalización IntracelularRESUMEN
Pediatric solid organ transplant (SOT) recipients face a challenging balance between immunosuppression and graft rejection. While Epstein-Barr Virus (EBV) and cytomegalovirus (HCMV) are known contributors to post-transplant lymphoproliferative disease and graft rejection, respectively, the roles of herpesvirus 6 and 7 (HHV6 and HHV7) and the impact of these herpesviruses on cytokine levels remain unclear, leading to gaps in clinical practice. In this associative study, we measured 17 cytokines using a Bio-Plex assay in a meticulously curated plasma sample pool (N = 158) from pediatric kidney and liver transplant recipients over a one-year follow-up period. The samples included virus-negative and virus-positive cases, either individually or in combination, along with episodes of graft rejection. We observed that the elevation of IL-4, IL-8, and IL-10 correlated with graft rejection. These cytokines were elevated in samples where HCMV or HHV6 were detected alone or where EBV and HHV7 were co-detected. Interestingly, latent EBV, when detected independently, exhibited an immunomodulatory effect by downregulating cytokine levels. However, in co-detection scenarios with ß-herpesviruses, EBV transitioned to a lytic state, also associating with heightened cytokinemia and graft rejection. These findings highlight the complex interactions between the immune response and herpesviruses in transplant recipients. The study advocates for enhanced monitoring of not only EBV and HCMV but also HHV6 and HHV7, providing valuable insights for improved risk assessment and targeted interventions in pediatric SOT recipients.
Asunto(s)
Citocinas , Citomegalovirus , Rechazo de Injerto , Herpesvirus Humano 6 , Herpesvirus Humano 7 , Trasplante de Riñón , Trasplante de Hígado , Humanos , Trasplante de Riñón/efectos adversos , Citocinas/sangre , Citocinas/metabolismo , Niño , Herpesvirus Humano 6/inmunología , Masculino , Femenino , Preescolar , Trasplante de Hígado/efectos adversos , Citomegalovirus/inmunología , Rechazo de Injerto/virología , Rechazo de Injerto/inmunología , Herpesvirus Humano 4/inmunología , Adolescente , Lactante , Infecciones por Herpesviridae/virología , Infecciones por Herpesviridae/inmunología , Receptores de Trasplantes , Infecciones por Virus de Epstein-Barr/virología , Infecciones por Virus de Epstein-Barr/inmunología , Infecciones por Citomegalovirus/virología , Infecciones por Citomegalovirus/inmunología , HerpesviridaeAsunto(s)
Infecciones por Virus de Epstein-Barr , Herpesvirus Humano 4 , Herpesvirus Humano 6 , Esclerosis Múltiple , Infecciones por Roseolovirus , Humanos , Infecciones por Roseolovirus/complicaciones , Infecciones por Virus de Epstein-Barr/complicaciones , Esclerosis Múltiple/virología , Esclerosis Múltiple/epidemiología , Factores de RiesgoRESUMEN
A previous study suggested that fetal inheritance of chromosomally integrated human herpesvirus 6 (ici-HHV6) is associated with the hypertensive pregnancy disorder preeclampsia (PE). We aimed to study this question utilizing cord plasma samples (n = 1276) of the Finnish Genetics of Preeclampsia Consortium (FINNPEC) cohort: 539 from a pregnancy with PE and 737 without. We studied these samples and 30 placentas from PE pregnancies by a multiplex qPCR for the DNAs of all nine human herpesviruses. To assess the population prevalence of iciHHV-6, we studied whole-genome sequencing data from blood-derived DNA of 3421 biobank subjects. Any herpes viral DNA was detected in only two (0.37%) PE and one (0.14%) control sample (OR 2.74, 95% CI 0.25-30.4). One PE sample contained iciHHV-6B and another HHV-7 DNA. The control's DNA was of iciHHV-6B; the fetus having growth restriction and preterm birth without PE diagnosis. Placentas showed no herpesviruses. In the biobank data, 3 of 3421 subjects (0.08%) had low level HHV-6B but no iciHHV-6. While iciHHV-6 proved extremely rare, both fetuses with iciHHV-6B were growth-restricted, preterm, and from a pregnancy with maternal hypertension. Our findings suggest that human herpesviruses are not a significant cause of PE, whereas iciHHV-6 may pose some fetal risk.
Asunto(s)
Herpesvirus Humano 6 , Preeclampsia , Humanos , Femenino , Embarazo , Preeclampsia/virología , Preeclampsia/epidemiología , Adulto , Herpesvirus Humano 6/genética , Herpesvirus Humano 6/aislamiento & purificación , Estudios de Cohortes , Sangre Fetal/virología , Finlandia/epidemiología , ADN Viral/genética , ADN Viral/sangre , Placenta/virología , Herpesviridae/genéticaRESUMEN
Human herpesvirus 6 (HHV-6) is a widely spread DNA virus that is ubiquitous and persistent with primary infection occurring in early childhood, with reactivation of the infection a common phenomenon in severely immunocompromised hosts, including hematopoietic stem cell transplant (HSCT) patients, influencing morbidity and mortality. A wide spectrum of clinical presentations is reported in the literature with HHV-6 reactivation including post-transplant limbic encephalitis (PALE). We report the unusual case of a 6-year-old female 107 days postallogenic HSCT due to transfusion dependent beta thalassemia major who developed acute cerebellitis with secondary supratentorial hydrocephalus that required invasive surgical intervention. In addition to accompanying imaging findings, the patient tested positive for HHV-6 by PCR from both serum and CSF samples and demonstrated dramatic improvement with the institution of steroid therapy in addition to ganciclovir treatment. The availability of rapid diagnostic measures in addition to a multidisciplinary approach is crucial to manage HHV-6 encephalitis and associated complications in HSCT patients.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Herpesvirus Humano 6 , Hidrocefalia , Infecciones por Roseolovirus , Humanos , Herpesvirus Humano 6/aislamiento & purificación , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Femenino , Hidrocefalia/etiología , Hidrocefalia/cirugía , Niño , Infecciones por Roseolovirus/virología , Infecciones por Roseolovirus/diagnóstico , Infecciones por Roseolovirus/complicaciones , Infecciones por Roseolovirus/tratamiento farmacológico , Antivirales/uso terapéutico , Encefalitis Viral/etiología , Encefalitis Viral/virología , Encefalitis Viral/diagnóstico , Encefalitis Viral/tratamiento farmacológico , Talasemia beta/complicaciones , Talasemia beta/terapia , Huésped InmunocomprometidoRESUMEN
Synergistic interactions between human herpesvirus 6A (HHV-6A) and Epstein-Barr virus (EBV) are hypothesized in the etiopathogenesis of multiple sclerosis (MS). This study investigated if HHV-6A and EBV seroreactivities interact regarding the risk of developing MS. Antibodies against viral antigens were analyzed in biobank samples from 670 individuals who later developed MS and matched controls. Additive interactions were analyzed. A significant interaction between HHV-6A and EBNA-1 seroreactivities was observed in study participants above the median age of 24.9 years (attributable proportion due to interaction = 0.45). This finding supports the hypothesis that HHV-6A and EBV infections interact in MS development. ANN NEUROL 2024;96:302-305.
Asunto(s)
Anticuerpos Antivirales , Infecciones por Virus de Epstein-Barr , Antígenos Nucleares del Virus de Epstein-Barr , Herpesvirus Humano 4 , Herpesvirus Humano 6 , Esclerosis Múltiple , Infecciones por Roseolovirus , Humanos , Herpesvirus Humano 6/inmunología , Esclerosis Múltiple/virología , Esclerosis Múltiple/inmunología , Herpesvirus Humano 4/inmunología , Femenino , Estudios de Casos y Controles , Masculino , Adulto , Infecciones por Virus de Epstein-Barr/inmunología , Infecciones por Virus de Epstein-Barr/complicaciones , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Antígenos Nucleares del Virus de Epstein-Barr/inmunología , Infecciones por Roseolovirus/inmunología , Infecciones por Roseolovirus/complicaciones , Adulto Joven , Persona de Mediana Edad , AdolescenteRESUMEN
INTRODUCTION: SARS-CoV-2 infection causes immune disorders that create conditions for the reactivation of human herpesviruses (HHVs). However, the estimates of the HHVs effect on the course and outcome of COVID-19 are ambiguous. Ðim - to study the possible relationship between the HHV reactivation and the adverse outcome of COVID-19. MATERIALS AND METHODS: Postmortem samples from the brain, liver, spleen, lymph nodes and lungs were obtained from 59 patients treated at the Moscow Infectious Diseases Hospital No.1 in 2021-2023. The group 1 comprised 39 patients with fatal COVID-19; group 2 (comparison group) included 20 patients not infected with SARS-CoV-2 who died from various somatic diseases. HHV DNA and SARS-CoV-2 RNA were determined by PCR. RESULTS: HHV DNA was found in autopsy samples from all patients. In group 1, EBV was most often detected in lymph nodes (94%), HHV-6 in liver (68%), CMV in lymph nodes (18%), HSV in brain (16%), VZV in lung and spleen (3% each). The detection rates of HHVs in both groups was similar. Important differences were found in viral load. In patients with COVID-19, the number of samples containing more than 1,000 copies of HHV DNA per 100,000 cells was 52.4%, in the comparison group - 16.6% (p < 0.002). An association has been established between the reactivation of HSV and HHV-6 and the severity of lung damage. Reactivation of EBV correlated with increased levels of liver enzymes. CONCLUSION: Reactivation of HHVs in patients with fatal COVID-19 was associated with severe lung and liver damages, which indicates a link between HHV reactivation and COVID-19 deaths.
Asunto(s)
Autopsia , COVID-19 , ADN Viral , Infecciones por Herpesviridae , Herpesviridae , SARS-CoV-2 , Humanos , COVID-19/virología , COVID-19/mortalidad , COVID-19/diagnóstico , COVID-19/patología , Femenino , Masculino , ADN Viral/genética , SARS-CoV-2/genética , SARS-CoV-2/aislamiento & purificación , Persona de Mediana Edad , Anciano , Herpesviridae/genética , Herpesviridae/aislamiento & purificación , Infecciones por Herpesviridae/virología , Infecciones por Herpesviridae/mortalidad , Adulto , Pulmón/virología , Pulmón/patología , Activación Viral , Herpesvirus Humano 6/genética , Herpesvirus Humano 6/aislamiento & purificación , Moscú , Carga Viral , Ganglios Linfáticos/virología , Ganglios Linfáticos/patología , Anciano de 80 o más Años , Bazo/virología , Bazo/patologíaRESUMEN
Acute severe hepatitis associated with active human herpesvirus 6 (HHV-6) infection is a rare life-threatening condition with unclear clinical course and histopathology. In this study, we retrospectively analyzed 5 patients with indeterminate acute severe hepatitis found to have active hepatic HHV-6 infection during care. All patients were previously healthy children presenting with a nonspecific prodrome. Four developed acute liver failure (ALF) and 3 received liver transplantation. The explanted livers and biopsies demonstrated a centrilobular pattern of necroinflammation characterized by moderate to marked central perivenulitis and confluent centrilobular to panlobular necrosis in 4 cases, accompanied by marked hepatocellular swelling and milder portal inflammation in 3. Central perivenulitis was more prominent in comparison to a control of group of ALF without HHV-6 ( P =0.01). When compared with the children with acute severe hepatitis associated with adenovirus encountered in the recent outbreak, both central perivenulitis and centrilobular necrosis were significant predictors for association with HHV-6 ( P <0.01). Liver immunohistochemistry detected HHV-6 structural protein in biliary epithelium in all cases and a predominance of CD8 + T cells in the perivenular inflammatory infiltrate. Among the 4 patients with ALF, one received early anti-HHV-6 therapy and had transplant-free survival, while the other 3 received either general prophylactic antiviral treatment only (n=2) or late anti-HHV-6 therapy (n=1) and needed liver transplantation. Our findings were similar to those in previously reported cases. In summary, acute severe hepatitis associated with HHV-6 tends to affect children, progress to ALF, and exhibit characteristic centrilobular necroinflammation which likely represents an immune-mediated process.
Asunto(s)
Herpesvirus Humano 6 , Trasplante de Hígado , Infecciones por Roseolovirus , Humanos , Herpesvirus Humano 6/aislamiento & purificación , Masculino , Estudios Retrospectivos , Infecciones por Roseolovirus/patología , Infecciones por Roseolovirus/virología , Infecciones por Roseolovirus/complicaciones , Femenino , Preescolar , Niño , Lactante , Enfermedad Aguda , Hepatitis Viral Humana/patología , Hepatitis Viral Humana/virología , Fallo Hepático Agudo/virología , Fallo Hepático Agudo/patología , Índice de Severidad de la Enfermedad , Hígado/patología , Hígado/virología , Inmunohistoquímica , Biopsia , AdolescenteAsunto(s)
Síndrome de Hipersensibilidad a Medicamentos , Herpesvirus Humano 6 , Linfadenitis , Linfoma , Infecciones por Roseolovirus , Humanos , Herpesvirus Humano 6/aislamiento & purificación , Linfadenitis/virología , Linfadenitis/diagnóstico , Linfadenitis/etiología , Infecciones por Roseolovirus/complicaciones , Infecciones por Roseolovirus/diagnóstico , Síndrome de Hipersensibilidad a Medicamentos/diagnóstico , Síndrome de Hipersensibilidad a Medicamentos/etiología , Síndrome de Hipersensibilidad a Medicamentos/patología , Linfoma/complicaciones , Diagnóstico Diferencial , Masculino , Femenino , Persona de Mediana EdadAsunto(s)
Síndrome de Hipersensibilidad a Medicamentos , Herpesvirus Humano 6 , Infecciones por Roseolovirus , Activación Viral , Femenino , Humanos , Masculino , Persona de Mediana Edad , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/diagnóstico , Síndrome de Hipersensibilidad a Medicamentos/diagnóstico , Síndrome de Hipersensibilidad a Medicamentos/etiología , Síndrome de Hipersensibilidad a Medicamentos/virología , Eosinofilia/inducido químicamente , Eosinofilia/diagnóstico , Eosinofilia/virología , Herpesvirus Humano 6/aislamiento & purificación , Infección Latente , Infecciones por Roseolovirus/diagnóstico , Infecciones por Roseolovirus/complicacionesRESUMEN
PURPOSE OF REVIEW: Viral infections continue to burden allogeneic hematopoietic cell transplant (HCT) recipients. We review the epidemiology, diagnosis, and management of human herpesvirus (HHV)-6, HHV-8 and parvovirus B19 following HCT. RECENT FINDINGS: Advances in HCT practices significantly improved outcomes but impact viral epidemiology: post-transplant cyclophosphamide for graft-versus-host disease prevention increases HHV-6 reactivation risk while the impact of letermovir for CMV prophylaxis - and resulting decrease in broad-spectrum antivirals - is more complex. Beyond the well established HHV-6 encephalitis, recent evidence implicates HHV-6 in pneumonitis. Novel less toxic therapeutic approaches (brincidofovir, virus-specific T-cells) may enable preventive strategies in the future. HHV-8 is the causal agent of Kaposi's sarcoma, which is only sporadically reported after HCT, but other manifestations are possible and not well elucidated. Parvovirus B19 can cause severe disease post-HCT, frequently manifesting with anemia, but can also be easily overlooked due to lack of routine screening and ambiguity of manifestations. SUMMARY: Studies should establish the contemporary epidemiology of HHV-6, and other more insidious viruses, such as HHV-8 and parvovirus B19 following HCT and should encompass novel cellular therapies. Standardized and readily available diagnostic methods are key to elucidate epidemiology and optimize preventive and therapeutic strategies to mitigate the burden of infection.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Herpesvirus Humano 6 , Herpesvirus Humano 8 , Parvovirus B19 Humano , Humanos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Parvovirus B19 Humano/aislamiento & purificación , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/diagnóstico , Antivirales/uso terapéutico , Infecciones por Roseolovirus/epidemiología , Infecciones por Roseolovirus/virología , Infecciones por Roseolovirus/diagnóstico , Trasplante Homólogo/efectos adversos , Infecciones por Herpesviridae/epidemiología , Infecciones por Herpesviridae/virologíaAsunto(s)
Síndrome de Hipersensibilidad a Medicamentos , Herpesvirus Humano 6 , Infecciones por Roseolovirus , Activación Viral , Humanos , Herpesvirus Humano 6/aislamiento & purificación , Infecciones por Roseolovirus/diagnóstico , Infecciones por Roseolovirus/complicaciones , Síndrome de Hipersensibilidad a Medicamentos/diagnóstico , Síndrome de Hipersensibilidad a Medicamentos/etiología , Síndrome de Hipersensibilidad a Medicamentos/virología , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/diagnóstico , Eosinofilia/inducido químicamente , Eosinofilia/virología , Eosinofilia/diagnóstico , Infección LatenteRESUMEN
Sudden cardiac death (SCD) is a major public health issue worldwide. In the young (< 40 years of age), genetic cardiomyopathies and viral myocarditis, sometimes in combination, are the most frequent, but underestimated, causes of SCD. Molecular autopsy is essential for prevention. Several studies have shown an association between genetic cardiomyopathies and viral myocarditis, which is probably underestimated due to insufficient post-mortem investigations. We report on four autopsy cases illustrating the pathogenesis of these combined pathologies. In two cases, a genetic hypertrophic cardiomyopathy was diagnosed in combination with Herpes Virus Type 6 (HHV6) and/or Parvovirus-B19 (PVB19) in the heart. In the third case, autopsy revealed a dilated cardiomyopathy and virological analyses revealed acute myocarditis caused by three viruses: PVB19, HHV6 and Epstein-Barr virus. Genetic analyses revealed a mutation in the gene coding for desmin. The fourth case illustrated a channelopathy and a PVB19/HHV6 coinfection. Our four cases illustrate the highly probable deleterious role of cardiotropic viruses in the occurrence of SCD in subjects with genetic cardiomyopathies. We discuss the pathogenetic link between viral myocarditis and genetic cardiomyopathy. Molecular autopsy is essential in prevention of these SCD, and a close collaboration between cardiologists, pathologists, microbiologists and geneticians is mandatory.
Asunto(s)
Autopsia , Muerte Súbita Cardíaca , Herpesvirus Humano 6 , Miocarditis , Parvovirus B19 Humano , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Cardiomiopatía Dilatada/genética , Cardiomiopatía Dilatada/virología , Cardiomiopatía Dilatada/patología , Cardiomiopatía Hipertrófica/genética , Cardiomiopatía Hipertrófica/patología , Causas de Muerte , Coinfección , Muerte Súbita Cardíaca/etiología , Muerte Súbita Cardíaca/patología , Muerte Súbita Cardíaca/prevención & control , Infecciones por Virus de Epstein-Barr/complicaciones , Resultado Fatal , Predisposición Genética a la Enfermedad , Herpesvirus Humano 4/genética , Herpesvirus Humano 6/genética , Herpesvirus Humano 6/aislamiento & purificación , Mutación , Miocarditis/virología , Miocarditis/patología , Miocarditis/genética , Infecciones por Parvoviridae/complicaciones , Parvovirus B19 Humano/genética , Infecciones por Roseolovirus/complicaciones , Infecciones por Roseolovirus/virología , Infecciones por Roseolovirus/diagnóstico , Infecciones por Roseolovirus/patologíaRESUMEN
BACKGROUND AND AIMS: An increase in the number of cases of acute hepatitis of unknown origin (HUO) in children was observed in 2021. Adenovirus and adeno-associated virus 2 (AAV2) infections have been suggested as possible triggers. However, the potential etiology is still unclear. We aimed to characterize a cohort of children with HUO in Israel in view of the COVID-19 pandemic. METHOD: Demographics, clinical data, and laboratory results on the children compatible with the CDC criteria for HUO were collected by the established registry of the Ministry of Health. Available specimens were sent to the Central Virology Laboratory. RESULTS: A total of 39 children were included in the registry. A total of 20 were enrolled prospectively, in which human herpes virus 6 (HHV6) infection or reactivation was identified in 11/19, adenovirus was found in 4/19 of the cases, and AAV2 was detected in 2/16. Past COVID-19 exposure was recorded for 24/39 of the children. A total of 10 children underwent liver biopsy, and 8 were successfully treated with steroids and 2 underwent liver transplantation. CONCLUSIONS: The COVID-19 pandemic and the related containment measures combined with reactivation or active infection with other viruses could have been a trigger for the HUO outbreak. In our cohort, HHV6 was the most abundant finding.
Asunto(s)
COVID-19 , SARS-CoV-2 , Humanos , COVID-19/epidemiología , COVID-19/virología , Niño , Femenino , Masculino , Preescolar , Lactante , Israel/epidemiología , Adolescente , Herpesvirus Humano 6/fisiología , Brotes de Enfermedades , Estudios Prospectivos , Enfermedad Aguda/epidemiología , PandemiasRESUMEN
HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant (HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following HCT and is associated with pleiotropic manifestations in this setting, including graft-versus-host disease, myelosuppression, pneumonitis, and CMV reactivation, although the causal link is not always clear. When the virus inserts its genome in chromosomes of germ cells, the chromosomally integrated form (ciHHV6) is inherited by offspring. The condition of ciHHV6 is characterized by the persistent detection of HHV-6 DNA, often confounding diagnosis of reactivation and disease-this has also been associated with adverse outcomes. Recent changes in clinical practice in the field of cellular therapies, including a wider use of post-HCT cyclophosphamide, the advent of letermovir for CMV prophylaxis, and the rapid expansion of novel cellular therapies require contemporary epidemiological studies to determine the pathogenic role and spectrum of disease of HHV-6B in the current era. Research into the epidemiology and clinical significance of HHV-6B in chimeric antigen receptor T cell (CAR-T cell) therapy recipients is in its infancy. No controlled trials have determined the optimal treatment for HHV-6B. Treatment is reserved for end-organ disease, and the choice of antiviral agent is influenced by expected toxicities. Virus-specific T cells may provide a novel, less toxic therapeutic modality but is more logistically challenging. Preventive strategies are hindered by the high toxicity of current antivirals. Ongoing study is needed to keep up with the evolving epidemiology and impact of HHV-6 in diverse and expanding immunocompromised patient populations.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Herpesvirus Humano 6 , Receptores Quiméricos de Antígenos , Infecciones por Roseolovirus , Activación Viral , Herpesvirus Humano 6/inmunología , Herpesvirus Humano 6/genética , Herpesvirus Humano 6/fisiología , Humanos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Infecciones por Roseolovirus/virología , Infecciones por Roseolovirus/inmunología , Infecciones por Roseolovirus/terapia , Receptores Quiméricos de Antígenos/inmunología , Receptores Quiméricos de Antígenos/genética , Inmunoterapia Adoptiva/métodos , Inmunoterapia Adoptiva/efectos adversos , Enfermedad Injerto contra Huésped/inmunología , Enfermedad Injerto contra Huésped/etiologíaRESUMEN
AMP-activated protein kinase (AMPK) is a cellular energy sensor regulating metabolic homeostasis. In this study, we investigated the role of AMPK in response to human herpesvirus 6A (HHV-6A) infection. We show that HHV-6A infection significantly downregulates the active phosphorylated state of AMPK in infected T cells. Pharmacological activation of AMPK highly attenuated HHV-6A propagation. Mechanistically, we found that the activation of AMPK by AICAR blocked HHV-6-induced glycolysis by inhibiting glucose metabolism and lactate secretion, as well as decreasing expressions of key glucose transporters and glycolytic enzymes. In addition, mTOR signaling has been inactivated in HHV-6A infected T cells by AICAR treatment. We also showed that HHV-6A infection of human umbilical cord blood mononuclear cells (CBMCs) reduced AMPK activity whereas the activation of AMPK by metformin drastically reduced HHV-6A DNA replication and virions production. Taken together, this study demonstrates that AMPK is a promising antiviral therapeutic target against HHV-6A infection.
Asunto(s)
Proteínas Quinasas Activadas por AMP , Glucólisis , Herpesvirus Humano 6 , Transducción de Señal , Serina-Treonina Quinasas TOR , Replicación Viral , Herpesvirus Humano 6/fisiología , Herpesvirus Humano 6/genética , Herpesvirus Humano 6/metabolismo , Humanos , Replicación Viral/efectos de los fármacos , Serina-Treonina Quinasas TOR/metabolismo , Serina-Treonina Quinasas TOR/genética , Proteínas Quinasas Activadas por AMP/metabolismo , Proteínas Quinasas Activadas por AMP/genética , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/farmacología , Infecciones por Roseolovirus/virología , Infecciones por Roseolovirus/metabolismo , Metformina/farmacología , Ribonucleótidos/farmacología , FosforilaciónRESUMEN
Human herpesvirus type 6A (HHV-6A) can cause a series of immune and neurological diseases, and the establishment of a sensitive biosensor for the rapid detection of HHV-6A is of great significance for public health and safety. Herein, a bis-tridentate iridium complex (BisLT-Ir-NHC) comprising the N-heterocyclic carbene (NHC) ligand as a novel kind of efficient ECL luminophore has been unprecedently reported. Based on its excellent ECL properties, a new sensitive ECL-based sandwich immunosensor to detect the HHV-6A virus was successfully constructed by encapsulating BisLT-Ir-NHC into silica nanoparticles and embellishing ECL sensing interface with MXene@Au-CS. Notably, the immunosensor illustrated in this work not only had a wide linear range of 102 to 107 cps/µL but also showed outstanding recoveries (98.33-105.11%) in real human serum with an RSD of 0.85-3.56%. Undoubtedly, these results demonstrated the significant potential of the bis-tridentate iridium(III) complex containing an NHC ligand in developing ECL-based sensitive analytical methods for virus detection and exploring novel kinds of efficient iridium-based ECL luminophores in the future.
Asunto(s)
Complejos de Coordinación , Técnicas Electroquímicas , Herpesvirus Humano 6 , Iridio , Mediciones Luminiscentes , Metano/análogos & derivados , Iridio/química , Humanos , Inmunoensayo/métodos , Ligandos , Complejos de Coordinación/química , Mediciones Luminiscentes/métodos , Técnicas Electroquímicas/métodos , Metano/química , Compuestos Heterocíclicos/químicaRESUMEN
ABSTRACT: Human herpesvirus 6B (HHV-6B) reactivation and disease are increasingly reported after chimeric antigen receptor (CAR) T-cell therapy (CARTx). HHV-6 reactivation in the CAR T-cell product was recently reported, raising questions about product and patient management. Because of overlapping manifestations with immune effector cell-associated neurotoxicity syndrome, diagnosing HHV-6B encephalitis is challenging. We provide 2 lines of evidence assessing the incidence and outcomes of HHV-6B after CARTx. First, in a prospective study with weekly HHV-6B testing for up to 12 weeks after infusion, HHV-6B reactivation occurred in 8 of 89 participants; 3 had chromosomally integrated HHV-6 and were excluded, resulting in a cumulative incidence of HHV-6B reactivation of 6% (95% confidence interval [CI], 2.2-12.5). HHV-6B detection was low level (median peak, 435 copies per mL; interquartile range, 164-979) and did not require therapy. Second, we retrospectively analyzed HHV-6B detection in the blood and/or cerebrospinal fluid (CSF) within 12 weeks after infusion in CARTx recipients. Of 626 patients, 24 had symptom-driven plasma testing, with detection in 1. Among 34 patients with CSF HHV-6 testing, 1 patient had possible HHV-6 encephalitis for a cumulative incidence of 0.17% (95% CI, 0.02-0.94), although symptoms improved without treatment. Our data demonstrate that HHV-6B reactivation and disease are infrequent after CARTx. Routine HHV-6 monitoring is not warranted.
Asunto(s)
Herpesvirus Humano 6 , Inmunoterapia Adoptiva , Receptores Quiméricos de Antígenos , Infecciones por Roseolovirus , Activación Viral , Humanos , Herpesvirus Humano 6/inmunología , Masculino , Femenino , Persona de Mediana Edad , Adulto , Infecciones por Roseolovirus/inmunología , Infecciones por Roseolovirus/virología , Infecciones por Roseolovirus/terapia , Infecciones por Roseolovirus/diagnóstico , Receptores Quiméricos de Antígenos/inmunología , Activación Viral/inmunología , Inmunoterapia Adoptiva/métodos , Inmunoterapia Adoptiva/efectos adversos , Anciano , Estudios Prospectivos , Estudios Retrospectivos , Adulto Joven , IncidenciaRESUMEN
BACKGROUND: Persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), reactivation of dormant viruses, and immune-oxidative responses are involved in long COVID. OBJECTIVES: To investigate whether long COVID and depressive, anxiety, and chronic fatigue syndrome (CFS) symptoms are associated with IgA/IgM/IgG to SARS-CoV-2, human herpesvirus type 6 (HHV-6), Epstein-Barr Virus (EBV), and immune-oxidative biomarkers. METHODS: We examined 90 long COVID patients and ninety healthy controls. We measured serum IgA/IgM/IgG against HHV-6 and EBV and their deoxyuridine 5'-triphosphate nucleotidohydrolase (duTPase), SARS-CoV-2, and activin-A, C-reactive protein (CRP), advanced oxidation protein products (AOPP), and insulin resistance (HOMA2-IR). RESULTS: Long COVID patients showed significant elevations in IgG/IgM-SARS-CoV-2, IgG/IgM-HHV-6, and HHV-6-duTPase, IgA/IgM-activin-A, CRP, AOPP, and HOMA2-IR. Neural network analysis yielded a highly significant predictive accuracy of 80.6% for the long COVID diagnosis (sensitivity: 78.9%, specificity: 81.8%, area under the ROC curve = 0.876); the topmost predictors were as follows: IGA-activin-A, IgG-HHV-6, IgM-HHV-6-duTPase, IgG-SARS-CoV-2, and IgM-HHV-6 (all positively) and a factor extracted from all IgA levels to all viral antigens (inversely). The top 5 predictors of affective symptoms due to long COVID were IgM-HHV-6-duTPase, IgG-HHV-6, CRP, education, IgA-activin-A (predictive accuracy of r = 0.636). The top 5 predictors of CFS due to long COVID were in descending order: CRP, IgG-HHV-6-duTPase, IgM-activin-A, IgM-SARS-CoV-2, and IgA-activin-A (predictive accuracy: r = 0.709). CONCLUSION: Reactivation of HHV-6, SARS-CoV-2 persistence, and autoimmune reactions to activin-A combined with activated immune-oxidative pathways play a major role in the pathophysiology of long COVID as well as the severity of its affective symptoms and CFS.